<PubmedArticle>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">18423261</PMID>
<DateCompleted>
<Year>2008</Year>
<Month>05</Month>
<Day>07</Day>
</DateCompleted>
<DateRevised>
<Year>2018</Year>
<Month>12</Month>
<Day>01</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1097-6787</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>58</Volume>
<Issue>5</Issue>
<PubDate>
<Year>2008</Year>
<Month>May</Month>
</PubDate>
</JournalIssue>
<Title>Journal of the American Academy of Dermatology</Title>
<ISOAbbreviation>J. Am. Acad. Dermatol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics.</ArticleTitle>
<Pagination>
<MedlinePgn>851-64</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jaad.2008.02.040</ELocationID>
<Abstract>
<AbstractText>Psoriasis is a common, chronic, inflammatory, multisystem disease with predominantly skin and joint manifestations affecting approximately 2% of the population. In this second of 5 sections of the guidelines of care for psoriasis, we give an overview of psoriatic arthritis including its cardinal clinical features, pathogenesis, prognosis, classification, assessment tools used to evaluate psoriatic arthritis, and the approach to treatment. Although patients with mild to moderate psoriatic arthritis may be treated with nonsteroidal anti-inflammatory drugs and/or intra-articular steroid injections, the use of disease-modifying antirheumatic drugs, particularly methotrexate, along with the biologic agents, are considered the standard of care in patients with more significant psoriatic arthritis. We will discuss the use of disease-modifying antirheumatic drugs and the biologic therapies in the treatment of patients with moderate to severe psoriatic arthritis.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Gottlieb</LastName>
<ForeName>Alice</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Department of Dermatology, Tufts-New England Medical Center, Tufts University School of Medicine, Boston, Massachusetts, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Korman</LastName>
<ForeName>Neil J</ForeName>
<Initials>NJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Gordon</LastName>
<ForeName>Kenneth B</ForeName>
<Initials>KB</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Feldman</LastName>
<ForeName>Steven R</ForeName>
<Initials>SR</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lebwohl</LastName>
<ForeName>Mark</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Koo</LastName>
<ForeName>John Y M</ForeName>
<Initials>JY</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Van Voorhees</LastName>
<ForeName>Abby S</ForeName>
<Initials>AS</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Elmets</LastName>
<ForeName>Craig A</ForeName>
<Initials>CA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Leonardi</LastName>
<ForeName>Craig L</ForeName>
<Initials>CL</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Beutner</LastName>
<ForeName>Karl R</ForeName>
<Initials>KR</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bhushan</LastName>
<ForeName>Reva</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Menter</LastName>
<ForeName>Alan</ForeName>
<Initials>A</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016446">Consensus Development Conference</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D017065">Practice Guideline</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Am Acad Dermatol</MedlineTA>
<NlmUniqueID>7907132</NlmUniqueID>
<ISSNLinking>0190-9622</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018501">Antirheumatic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D001688">Biological Products</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018124">Receptors, Tumor Necrosis Factor</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011993">Recombinant Fusion Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>ELK3V90G6C</RegistryNumber>
<NameOfSubstance UI="D000077944">Alefacept</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>FYS6T7F842</RegistryNumber>
<NameOfSubstance UI="D000068879">Adalimumab</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>OP401G7OJC</RegistryNumber>
<NameOfSubstance UI="D000068800">Etanercept</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>YL5FZ2Y5U1</RegistryNumber>
<NameOfSubstance UI="D008727">Methotrexate</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000068879">Adalimumab</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000077944">Alefacept</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000911">Antibodies, Monoclonal</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D061067">Antibodies, Monoclonal, Humanized</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018501">Antirheumatic Agents</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015535">Arthritis, Psoriatic</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000145">classification</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001688">Biological Products</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000068800">Etanercept</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019317">Evidence-Based Medicine</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007074">Immunoglobulin G</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008727">Methotrexate</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011788">Quality of Life</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018124">Receptors, Tumor Necrosis Factor</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011993">Recombinant Fusion Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014409">Tumor Necrosis Factor-alpha</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
</MeshHeading>
</MeshHeadingList>
<NumberOfReferences>34</NumberOfReferences>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="received">
<Year>2008</Year>
<Month>02</Month>
<Day>27</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised">
<Year>2008</Year>
<Month>02</Month>
<Day>27</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted">
<Year>2008</Year>
<Month>02</Month>
<Day>28</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2008</Year>
<Month>4</Month>
<Day>22</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2008</Year>
<Month>5</Month>
<Day>8</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez">
<Year>2008</Year>
<Month>4</Month>
<Day>22</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">18423261</ArticleId>
<ArticleId IdType="pii">S0190-9622(08)00274-0</ArticleId>
<ArticleId IdType="doi">10.1016/j.jaad.2008.02.040</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>